BRC Therapeutics Applauds Executive Order to Reclassify Cannabis
Positioned to Accelerate Downgrading of Cannabinoid Medicine Scheduling.
MONTEREY, Calif., Dec. 19, 2025 /PRNewswire/ — BRC Therapeutics (BRC), a pharmaceutical company developing proprietary therapeutics for neurological and inflammatory diseases, celebrates yesterday’s landmark executive order that would remove cannabis from a group of drugs classified as more dangerous than others, the so-called Schedule I drugs under the Controlled Substances Act. Cannabis’ classification would become a Schedule III drug.
This major shift at the federal level would move drug policy closer to what 40 states have already implemented and underscores the therapeutic potential of cannabis‑derived compounds or cannabinoids. The order is expected to accelerate a process that was initiated several years ago and would greatly facilitate the development and commercialization of cannabinoid medicines.
BRC is already operating in a federally compliant framework under stringent oversight of the Drug Enforcement Agency (DEA), holding all required DEA licenses for research activities and production under cGMP. This transformative policy change would add momentum to the company’s quest to fill high unmet medical needs using botanically derived cannabinoid therapeutics.
“Reclassification of cannabis at the federal level represents a watershed moment for science, medicine, and the millions of patients waiting for meaningful new treatment options,” said George Hodgin, CEO and Founder of BRC Therapeutics. “For years, the Schedule I classification impeded research and innovation. Yesterday’s order bears the promise that a major barrier will be lifted soon.”
BRC’s pipeline includes two investigational products that are currently being tested in clinical trials for Complex Regional Pain Syndrome (CRPS) and Aromatase Inhibitor-Induced Arthralgia (AIIA), respectively. A regulatory shift prompted by the order would allow for accelerated development and increased scale.
“We believe that a rescheduling would further catalyze rigorous scientific inquiry and set the stage for a generation of non‑addictive, evidence‑based treatments for pain and other conditions where cannabinoids have clear therapeutic promise,” Hodgin added.
About BRC Therapeutics
BRC Therapeutics (BRC) is a pharmaceutical company focused on developing innovative therapeutics to deliver relief from pain and other symptoms in acute and chronic conditions. BRC’s medicines are multimodal and contain cannabinoids at defined ratios. BRC has developed a pipeline of prescription medicines addressing neurological and inflammatory conditions. Two investigational products are currently being tested in clinical trials for Complex Regional Pain Syndrome (CRPS) and Aromatase Inhibitor-Induced Arthralgia (AIIA), respectively. BRC is registered with the Drug Enforcement Administration and is based in Monterey, CA.
To learn more about BRC, visit https://brctherapeutics.com/.
Forward‑Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks, uncertainties and assumptions, including without limitation statements about the development, use, benefits and effects of Biopharmaceutical Research Company’s (BRC) therapeutic product candidate and related technology, future plans for the BRC’s business and growth, expected plans with respect to clinical trials, including the number of patients enrolled and timing of patient enrollment. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “design,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements. The forward-looking statements made herein speak only as of the date of this press release and, unless otherwise required by law, BRC does not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
View original content to download multimedia:https://www.prnewswire.com/news-releases/brc-therapeutics-applauds-executive-order-to-reclassify-cannabis-302647027.html
SOURCE Biopharmaceutical Research Company
You May Also Like
Unlocking Opportunities: Coinbase Derivative Blends Crypto ETFs and Tech Giants
Crossmint Partners with MoneyGram for USDC Remittances in Colombia
